|
Level
|
Parameter
|
Group
|
---|
Control
|
Empagliflozin
|
---|
| |
Body weight [gr]
|
413 ± 35
|
395 ± 37
|
Apical level
|
Systolic
|
LVESA [mm2]
|
16.4 ± 5.9
|
15.8 ± 5.3
|
LVIDs [mm]
|
4.2 ± 0.7
|
4.6 ± 0.7
|
Diastolic
|
LVEDA [mm2]
|
43.3 ± 4.9
|
39.2 ± 5.4
|
LVIDd [mm]
|
7.6 ± 0.6
|
7.0 ± 0.6
|
Function
|
FS [%]
|
39.7 ± 3.9
|
35.6 ± 3.8
|
FAC [%]
|
63.1 ± 3.7
|
59.0 ± 3.7
|
EF [%]
|
74.5 ± 6.4
|
70.4 ± 6.2
|
Papillary muscles level
|
Systolic
|
LVESA [mm2]
|
20.5 ± 4.3
|
26.2 ± 4.3
|
LVIDs [mm]
|
4.3 ± 0.6
|
4.9 ± 0.7
|
Diastolic
|
LVEDA [mm2]
|
51.2 ± 4.7
|
47.1 ± 4.6
|
LVIDd [mm]
|
7.5 ± 0.6
|
7.3 ± 0.5
|
Function
|
FS [%]
|
36.2 ± 3.1
|
39.7 ± 3.2
|
FAC [%]
|
52.3 ± 3.6
|
56.2 ± 4.0
|
EF [%]
|
69.9 ± 5.3
|
76.4 ± 5.4
|
- LVESA, LVEDA—LV end systolic and end diastolic area, respectively. LVIDs, LVIDd—LV end systolic and end diastolic internal diameter, respectively. FS fractional shortening, FAC fractional area change, EF ejection fraction